Výsledky vyhledávání - "MRD Negative"

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Akademický článek

Comparable outcomes in patients with B-cell acute lymphoblastic leukemia receiving haploidentical hematopoietic stem cell transplantation: Pretransplant minimal residual disease-negative complete remission following chimeric antigen receptor T-cell therapy versus chemotherapy

Autor: Ting-Ting Yang, Ye Meng, De-Lin Kong, Guo-Qing Wei, Ming-Ming Zhang, Wen-Jun Wu, Ji-Min Shi, Yi Luo, Yan-Min Zhao, Jian Yu, Rui-Rui Jing, Meng-Yu Zhao, Hou-Li Zhao, He Huang, Yong-Xian Hu

Publikováno v: Frontiers in Immunology, Vol 13 (2022)

IntroductionChimeric antigen receptor (CAR) T-cell (CAR-T) therapy followed by haploidentical hematopoietic stem cell transplantation (haplo-HSCT) markedly improves the long-term survival of patients with refractory/relapsed (R/R) B-cell acute lympho

Externí odkaz: https://doaj.org/article/d2dade5d80084fd29b673875840c94b1

Zobrazit plný text záznamu

Akademický článek

Identification of the Predictive Models for the Treatment Response of Refractory/Relapsed B-Cell ALL Patients Receiving CAR-T Therapy

Autor: Jingxian Gu, Sining Liu, Wei Cui, Haiping Dai, Qingya Cui, Jia Yin, Zheng Li, Liqing Kang, Huiying Qiu, Yue Han, Miao Miao, Suning Chen, Shengli Xue, Ying Wang, Zhengming Jin, Xiaming Zhu, Lei Yu, Depei Wu, Xiaowen Tang

Publikováno v: Frontiers in Immunology, Vol 13 (2022)

Background/AimsChimeric antigen receptor (CAR) T cells for refractory or relapsed (r/r) B-cell acute lymphoblastic leukemia (ALL) patients have shown promising clinical effectiveness. However, the factors impacting the clinical response of CAR-T ther

Externí odkaz: https://doaj.org/article/a944e1cba69d4ba8b716cb889307f8e2

Zobrazit plný text záznamu

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Detection of measurable residual disease may better predict outcomes than mutations based on next‐generation sequencing in acute myeloid leukaemia with biallelic mutations of CEBPA

Autor: Xiaohong Liu, Hao Jiang, Lizhong Gong, Ying Wu, Yu Wang, Jing Wang, Guo-Rui Ruan, Lan-Ping Xu, Xiao-Hui Zhang, Hong-Xia Shi, Jinsong Jia, Yue-Yun Lai, Lu Runqing, Sheng-Ye Lu, Xiao-Su Zhao, Kai-Yan Liu, Xiao-Jun Huang, Chen-Hua Yan, Qian Jiang

Publikováno v: British Journal of Haematology. 190:533-544

Acute myeloid leukaemia (AML) patients with biallelic mutations of CEBPA (bi CEBPA) have a 30-50% relapse rate. This study established the value of mutations based on next-generation sequencing (NGS) and multiparameter flow cytometric measurable resi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::035e6921a6cc356d08817d54f6d97f7b
https://doi.org/10.1111/bjh.16535

Zobrazit plný text záznamu

MRD negative CR after azacitidine and venetoclax in a young patient with AML, unfit for intensive induction followed by ASCT

Autor: Satyendra Katewa, Lalit Sharma, Aadesh Arora, Rahul Sharma, Ravikant Porwal, Ravi C Dara, Deepak Kumar Shukla

Publikováno v: Leukemia Research Reports
Leukemia Research Reports, Vol 16, Iss, Pp 100267-(2021)

A subset of AML patients are unfit for 7+3 induction at the time of diagnosis. Present case highlights the use of azacitidine and venetoclax in a patient with intermediate risk AML with WT-1 mutation,deemed unfit for intensive induction in view of po

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::65bc560985a46a93e41715c34437fddb
http://europepmc.org/articles/PMC8436161

Zobrazit plný text záznamu

Reduced-Intensity Induction with Dasatinib Vs. Hypercvad + 2nd Generation TKIs with MRD-Guided Follow-up Therapy Leads to Comparable Rates of MRD-Negative Remission While Reducing Transfusions and Neutropenia in Ph+ ALL

Publikováno v: Blood. 136:42-44

Background: Reduced-intensity induction (RII) with imatinib yields comparable outcomes to HyperCVAD with imatinib with fewer induction deaths and an improved CR rate in Ph+ ALL (Chalandon. Blood. 2015). Dasatinib with steroids also produces excellent

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::e381aee3f00c357a945cec277c6b177b
https://doi.org/10.1182/blood-2020-141264

Zobrazit plný text záznamu

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Prognostic significance of lymphocyte recovery in children with standard and high-risk precursor B acute lymphoblastic leukemia

Autor: Mohammad Abdelhaleem, Angela Punnett, Muhammad Asim, Rahul Naithani

Publikováno v: Pediatric Hematology Oncology Journal, Vol 4, Iss 2, Pp 51-55 (2019)

Background: The primary aim of this study was to determine if absolute lymphocyte count (ALC) at end of induction is an independent prognostic marker of event free survival (EFS) in children with precursor B-ALL. Material & Methods: This is a retrosp

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a4d6c637b0bf7df17088c940b42fab95
http://www.sciencedirect.com/science/article/pii/S2468124519302384

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání